Denali Therapeutics Files 8-K
Ticker: DNLI · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
Related Tickers: DNLI
TL;DR
Denali Therapeutics filed an 8-K on 4/2/25. Standard disclosure stuff.
AI Summary
On April 2, 2025, Denali Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Denali Therapeutics Inc. is providing updates or disclosures required by the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- 001-38311 (company) — SEC File Number
- 46-3872213 (company) — I.R.S. Employer Identification No.
- April 2, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by Denali Therapeutics Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is April 2, 2025.
What is Denali Therapeutics Inc.'s principal executive office address?
The address is 161 Oyster Point Blvd., South San Francisco, California 94080.
What is Denali Therapeutics Inc.'s telephone number?
The telephone number is (650) 866-8547.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Denali Therapeutics Inc. (DNLI).